Cargando…

Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function

Diabetic cardiomyopathy (DCM) is considered to be a critical contributor to the development of heart failure. Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor, has been shown to prevent cardiovascular events and reduce the incidence of heart failure in randomized clinical trials. How...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jinwu, Huang, Xinyuan, Liu, Hanjie, Chen, Yuhang, Li, Peipei, Liu, Lingling, Li, Jiashen, Ren, Yangxi, Huang, Junping, Xiong, Erya, Tian, Zhijie, Dai, Xiaozhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110219/ https://www.ncbi.nlm.nih.gov/pubmed/35585884 http://dx.doi.org/10.1155/2022/1122494

Ejemplares similares

Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
por: Trang, Nguyen Ngoc, et al.
Publicado: (2021)

Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy
por: Ren, Changzhen, et al.
Publicado: (2021)

Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis
por: Zou, Rongjun, et al.
Publicado: (2022)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats
por: Al-Rasheed, Nawal M., et al.
Publicado: (2017)

Empagliflozin protects diabetic pancreatic tissue from damage by inhibiting the activation of the NLRP3/caspase-1/GSDMD pathway in pancreatic β cells: in vitro and in vivo studies
por: Liu, Pan, et al.
Publicado: (2021)

Attenuation of Adverse Postinfarction Left Ventricular Remodeling with Empagliflozin Enhances Mitochondria-Linked Cellular Energetics and Mitochondrial Biogenesis
por: Song, Yang, et al.
Publicado: (2021)

Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats
por: Ala, Moein, et al.
Publicado: (2022)

Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy
por: Zhang, Lin, et al.
Publicado: (2023)

Modified rougan decoction attenuates hepatocyte apoptosis through ameliorating mitochondrial dysfunction by upregulated SIRT1/PGC-1α signaling pathway
por: Wang, Wenjia, et al.
Publicado: (2023)

Empagliflozin suppresses hedgehog pathway, alleviates ER stress, and ameliorates hepatic fibrosis in rats
por: Abdalla, Nourihan, et al.
Publicado: (2023)

Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study
por: Oka, Satoshi, et al.
Publicado: (2021)

Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats
por: Kuno, Atsushi, et al.
Publicado: (2020)

Inhibition of KMO Ameliorates Myocardial Ischemia Injury via Maintaining Mitochondrial Fusion and Fission Balance
por: Lai, Qiong, et al.
Publicado: (2023)

Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats
por: Ashraf, Ghulam Md, et al.
Publicado: (2021)

Empagliflozin Ameliorates Preeclampsia and Reduces Postpartum Susceptibility to Adriamycin in a Mouse Model Induced by Angiotensin Receptor Agonistic Autoantibodies
por: Zhai, Ruonan, et al.
Publicado: (2022)

Empagliflozin Ameliorates Progression From Prediabetes to Diabetes and Improves Hepatic Lipid Metabolism: A Systematic Review
por: Hossain, Md Fahad, et al.
Publicado: (2022)

Empagliflozin in Patients with Chronic Kidney Disease
por: Herrington, William G., et al.
Publicado: (2023)

Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK/SIRT-1/PGC-1α-mediated mitochondrial biogenesis
por: Chen, Meicong
Publicado: (2023)

Empagliflozin-Pretreated Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Attenuated Heart Injury
por: Chi, Boyu, et al.
Publicado: (2023)

Attenuation of Na/K-ATPase Mediated Oxidant Amplification with pNaKtide Ameliorates Experimental Uremic Cardiomyopathy
por: Liu, Jiang, et al.
Publicado: (2016)

Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice
por: Huang, Chiang-Chi, et al.
Publicado: (2021)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Anti-inflammatory potential of Empagliflozin
por: Pirklbauer, Markus
Publicado: (2021)

Drug eruption associated with empagliflozin
por: Yau, Kevin, et al.
Publicado: (2022)

Tetrahydrocurcumin Ameliorates Diabetic Cardiomyopathy by Attenuating High Glucose-Induced Oxidative Stress and Fibrosis via Activating the SIRT1 Pathway
por: Li, Kaifeng, et al.
Publicado: (2019)

Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease
por: Sawada, Takahiro, et al.
Publicado: (2020)

Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK)
por: Domon, Ayaka, et al.
Publicado: (2021)

Corrigendum: Attenuation of Na/K-ATPase Mediated Oxidant Amplification with pNaKtide Ameliorates Experimental Uremic Cardiomyopathy
por: Liu, Jiang, et al.
Publicado: (2017)

Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic Mice
por: Lu, Yun-hong, et al.
Publicado: (2020)

Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats
por: Lee, Ting-I, et al.
Publicado: (2019)

Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice
por: Kurtz, Ryan, et al.
Publicado: (2022)

Empagliflozin mitigates endothelial inflammation and attenuates endoplasmic reticulum stress signaling caused by sustained glycocalyx disruption
por: Campeau, Marc-Antoine, et al.
Publicado: (2022)

Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes
por: Scisciola, Lucia, et al.
Publicado: (2023)

Empagliflozin protects against renal ischemia/reperfusion injury in mice
por: Wang, Qifeng, et al.
Publicado: (2022)

Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy
por: Qiu, Zirui, et al.
Publicado: (2022)

Trehalose Ameliorates Diabetic Cardiomyopathy: Role of the PK2/PKR Pathway
por: Liu, Yuning, et al.
Publicado: (2021)

Dexmedetomidine ameliorates diabetic cardiomyopathy by inhibiting ferroptosis through the Nrf2/GPX4 pathway
por: Li, Fan, et al.
Publicado: (2023)

Icariin Ameliorates Diabetic Cardiomyopathy Through Apelin/Sirt3 Signalling to Improve Mitochondrial Dysfunction
por: Ni, Tingjuan, et al.
Publicado: (2020)

Galectin-3 Inhibition Ameliorates Streptozotocin-Induced Diabetic Cardiomyopathy in Mice
por: Zhu, Ning, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n46narc51l185ojld7j1gsem0k